Journals / Annals of Medical Sciences / 2002 / Cilt: 11 - Sayı: 2-3-4

Serum levels of interleukin-12 in Behçet's disease

Pages
41–44
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our results may suggest involvement of IL-12 in the pathogenesis of BD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Although the immunopathogenesis of Behçet's disease (BD) is not well defined, T helper 1 (Th1) cell related cytokines have been shown to be elevated in previous studies.
📊
Key Findings & Data:We aimed to investigate the role of interleukin-12 in BD since it has activator and stimulator effect on Th1 cells.
💡
Conclusion & Impact:Conclusion: Our results may suggest involvement of IL-12 in the pathogenesis of BD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: Although the immunopathogenesis of Behçet's disease (BD) is not well defined, T helper 1 (Th1) cell related cytokines have been shown to be elevated in previous studies. We aimed to investigate the role of interleukin-12 in BD since it has activator and stimulator effect on Th1 cells. Methods: Serum IL-12 levels were assessed in 36 BD patients (13 active BD and 23 inactive BD patients), in 23 rheumatoid arthritis (RA) patients and in 22 healthy controls (HC) using sandwich ELISA method. Erythrocyte sedimentation rate (ESR) and C-reactive protein were also studied. Results: Levels of serum IL-12 were found as 3.023±4.391 pg/mL in BD patients, 4.189±4.751 pg/mL in RA patients and 0.126±0.428 pg/mL in HC. Levels of IL-12 were found to be higher in BD patients when compared to HC (p= 0.000). There was no difference between BD and RA patients (p=0.335). Serum IL-12 levels in active BD (5.617±5.725 pg/mL) and inactive BD (1.557±2.563 pg/mL) patients were found to be elevated when compared to those in HC (p= 0.000 and p=0.004, respectively). When all BD patients were compared to HC, there was no significant difference in ESR or CRP levels (p>0.05), but active BD patients had higher levels of ESR and CRP than HC (p=0.000 and p=0.001, respectively). Conclusion: Our results may suggest involvement of IL-12 in the pathogenesis of BD.

🔖

Cite This Article

CANATAROĞLU, A., GÜNEŞAÇAR, R. (2022). Serum levels of interleukin-12 in Behçet's disease. Annals of Medical Sciences, Cilt: 11 - Sayı: 2-3-4, 41–44. https://ajindex.com/articles/447442

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Yazıcı H, Yurdakul S, Hamuryudan V. Behçet’s syn-drome. In: Klippel JH, Dieppe PA Eds. Rheumatology, London, Mosby International; 1998: 7/ 26.1-26.5. 2.Frassanito MA, Dammacco R, Cafforio P, et al. Th1 po-larization of the immune response in Behçet’s disease. A putative pathogenic role of interleukin-12. Arthritis Rheum, 1999; 42:1967-1974. 3.Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's dis-ease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol, 1997; 24:128-132. 4.Mantaş C, Direskeneli H, Ekşioğlu-Demiralp E, et al. Se-rum levels of Th2 cytokines IL-4 and IL-10 in Behçet's disease. J Rheumatol, 1999; 26:510-512. 5.D'Andrea A, Rengaraju M, Valiante NM, et al. Produc-tion of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.J Exp Med, 1992; 176:1387-1398. 6.Trinchieri G. Proinflammatory and immunoregulatoryfunctions of IL-12. Int Rev Immunol, 1998; 16:365-396. 7.International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet, 1990; 335:1078-1080., 8.Romagnani S. Th1 and Th2 in human diseases. Clin Im-munol Immunopathol, 1996; 80:225-235. 9.Freysdottir J, Lau SH, Fortune F. γδ T cells in Behçet’s disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol, 1999; 118:451-457. 10.Mc-Dyer JF, Wu CY, Seder RA. The regulation of IL-12: Its role in infectious, autoimmune, and allergic disease. J Allergy Clin Immunol, 1998; 102:11-15. 11.Bhakta BB, Brennan P, James TE, et al. Behçet’s disease: evaluation of a new instrument to measure clinical activ-ity. Rheumatology, 1999; 38:728-733. 12.Hamuryudan V, Fresko İ, Direskeneli H, et al. Evaluation of the Turkish translation of a disease activity form for Behçet’s syndrome. Rheumatology, 1999; 38:734-736. 13.Van den Berg W, Miossec P. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum, 1997; 40:2105-2115. 14.Müftüoğlu AU, Yazıcı H, Yurdakul S, et al. Behçet's dis-ease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity. Int J Derma-tol, 1986; 25:235-239.